Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease
Open Access
- 17 July 2020
- journal article
- review article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 10 (3) , 63
Abstract
Alzheimer’s disease (AD) is a commonly occurring neurodegenerative disease in the advanced-age population, with a doubling of prevalence for each 5 years of age above 60 years. In the past two decades, there has been a sustained effort to find suitable biomarkers that may not only aide with the diagnosis of AD early in the disease process but also predict the onset of the disease in asymptomatic individuals. Current diagnostic evidence is supportive of some biomarker candidates isolated from cerebrospinal fluid (CSF), including amyloid beta peptide (Aβ), total tau (t-tau), and phosphorylated tau (p-tau) as being involved in the pathophysiology of AD. However, there are a few biomarkers that have been shown to be helpful, such as proteomic, inflammatory, oral, ocular and olfactory in the early detection of AD, especially in the individuals with mild cognitive impairment (MCI). To date, biomarkers are collected through invasive techniques, especially CSF from lumbar puncture; however, non-invasive (radio imaging) methods are used in practice to diagnose AD. In order to reduce invasive testing on the patients, present literature has highlighted the potential importance of biomarkers in blood to assist with diagnosing AD.Keywords
This publication has 118 references indexed in Scilit:
- Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation CarriersScience Translational Medicine, 2013
- Evolution of the diagnostic criteria for degenerative and cognitive disordersCurrent Opinion in Neurology, 2011
- Epidemiology of Alzheimer diseaseNature Reviews Neurology, 2011
- Identifying and validating biomarkers for Alzheimer's diseaseTrends in Biotechnology, 2011
- Decreased Clearance of CNS β-Amyloid in Alzheimer’s DiseaseScience, 2010
- Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot studyBMC Neurology, 2010
- YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's DiseaseBiological Psychiatry, 2010
- Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairmentActa Neuropathologica, 2010
- Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal FluidBiological Psychiatry, 2009
- Prediction and longitudinal study of CSF biomarkers in mild cognitive impairmentNeurobiology of Aging, 2009